ECSP088978A - Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma - Google Patents

Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma

Info

Publication number
ECSP088978A
ECSP088978A EC2008008978A ECSP088978A ECSP088978A EC SP088978 A ECSP088978 A EC SP088978A EC 2008008978 A EC2008008978 A EC 2008008978A EC SP088978 A ECSP088978 A EC SP088978A EC SP088978 A ECSP088978 A EC SP088978A
Authority
EC
Ecuador
Prior art keywords
methyl
indol
phenyl
propenamide
ethyl
Prior art date
Application number
EC2008008978A
Other languages
English (en)
Spanish (es)
Inventor
Murat Acemoglu
Joel Slade
Joginder Singh Bajwa
David John Parker
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088978(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP088978A publication Critical patent/ECSP088978A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EC2008008978A 2006-06-12 2008-12-12 Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma ECSP088978A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80452706P 2006-06-12 2006-06-12
US86787806P 2006-11-30 2006-11-30

Publications (1)

Publication Number Publication Date
ECSP088978A true ECSP088978A (es) 2009-01-30

Family

ID=38832681

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008978A ECSP088978A (es) 2006-06-12 2008-12-12 Procedimiento para hacer n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida y materiales de partida para la misma

Country Status (31)

Country Link
US (2) US20090306405A1 (enExample)
EP (2) EP2032533B8 (enExample)
JP (2) JP5431926B2 (enExample)
KR (2) KR101493530B1 (enExample)
CN (4) CN102167678B (enExample)
AR (1) AR061296A1 (enExample)
AU (1) AU2007257883B2 (enExample)
BR (1) BRPI0712847A2 (enExample)
CA (1) CA2653657C (enExample)
CL (2) CL2007001691A1 (enExample)
DK (1) DK2032533T3 (enExample)
EC (1) ECSP088978A (enExample)
ES (2) ES2553255T3 (enExample)
GT (1) GT200800282A (enExample)
HR (1) HRP20130798T1 (enExample)
IL (2) IL195211A (enExample)
IN (1) IN2015DN00910A (enExample)
JO (1) JO2900B1 (enExample)
MA (1) MA30513B1 (enExample)
MX (2) MX2008015898A (enExample)
MY (1) MY147576A (enExample)
NO (1) NO341870B1 (enExample)
NZ (1) NZ572707A (enExample)
PE (2) PE20120221A1 (enExample)
PL (1) PL2032533T3 (enExample)
PT (1) PT2032533E (enExample)
RU (1) RU2448090C2 (enExample)
TN (1) TNSN08507A1 (enExample)
TW (1) TWI395734B (enExample)
WO (1) WO2007146718A2 (enExample)
ZA (1) ZA200809490B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000004075A1 (it) 2020-02-27 2021-08-27 Flamma Spa Processo per la preparazione di panobinostat

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB146260A (en) 1918-07-11 1921-08-11 Elektro Osmose Ag A process for preparing proteids charged with immune substances
GB8531612D0 (en) * 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AU2002237261A1 (en) 2001-01-09 2002-07-24 Novartis Pharma Gmbh Rapid method for screening compounds for in vivo activity
NZ544689A (en) 2001-11-06 2007-08-31 Novartis Ag Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
AU2007257882B2 (en) * 2006-06-12 2011-09-08 Secura Bio Inc. Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide

Also Published As

Publication number Publication date
CN103086944A (zh) 2013-05-08
EP2394991A1 (en) 2011-12-14
PL2032533T3 (pl) 2013-08-30
JP5809223B2 (ja) 2015-11-10
KR20140117703A (ko) 2014-10-07
JP5431926B2 (ja) 2014-03-05
HK1126759A1 (en) 2009-09-11
NO341870B1 (no) 2018-02-12
IL233836A0 (en) 2014-09-30
AU2007257883A1 (en) 2007-12-21
PE20120221A1 (es) 2012-03-21
NZ572707A (en) 2011-12-22
CN102167678B (zh) 2013-08-28
US8536346B2 (en) 2013-09-17
CL2010000973A1 (es) 2011-07-01
CN102174008A (zh) 2011-09-07
WO2007146718A2 (en) 2007-12-21
CN102167678A (zh) 2011-08-31
KR101540194B1 (ko) 2015-07-28
BRPI0712847A2 (pt) 2012-08-07
ES2553255T3 (es) 2015-12-07
TW200815345A (en) 2008-04-01
RU2008151726A (ru) 2010-07-20
KR101493530B1 (ko) 2015-02-13
MX2008015898A (es) 2009-01-12
HK1162029A1 (en) 2012-08-17
DK2032533T3 (da) 2013-07-01
WO2007146718A3 (en) 2008-06-19
ZA200809490B (en) 2009-10-28
HRP20130798T1 (en) 2013-09-30
RU2448090C2 (ru) 2012-04-20
JO2900B1 (en) 2015-09-15
EP2032533B1 (en) 2013-04-03
GT200800282A (es) 2009-03-09
PE20080851A1 (es) 2008-08-18
NO20090137L (no) 2009-03-03
ES2416286T3 (es) 2013-07-31
AR061296A1 (es) 2008-08-20
KR20090015969A (ko) 2009-02-12
US20090306405A1 (en) 2009-12-10
CN101466674A (zh) 2009-06-24
TNSN08507A1 (en) 2010-04-14
PT2032533E (pt) 2013-06-28
EP2394991B1 (en) 2015-09-23
US20120010418A1 (en) 2012-01-12
CA2653657A1 (en) 2007-12-21
MY147576A (en) 2012-12-31
JP2014058532A (ja) 2014-04-03
TWI395734B (zh) 2013-05-11
MX366213B (es) 2019-07-01
IL195211A (en) 2014-08-31
EP2032533B8 (en) 2013-12-11
IL195211A0 (en) 2009-08-03
CL2007001691A1 (es) 2008-05-16
IN2015DN00910A (enExample) 2015-07-10
MA30513B1 (fr) 2009-06-01
IL233836A (en) 2017-05-29
EP2032533A2 (en) 2009-03-11
JP2009540008A (ja) 2009-11-19
AU2007257883B2 (en) 2011-09-29
CA2653657C (en) 2015-10-27

Similar Documents

Publication Publication Date Title
CR10439A (es) Sales de n-hidroxi-3-[4-[[[2-(metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
EA200802383A1 (ru) Полиморфные формы n-гидрокси-3-[4-[[[2-(2-метил-1h-индол-3-ил)этил]амино]метил]фенил]-2e-2-акриламида
JO3099B1 (ar) طريقة تصنيع املاح من n- هيدروكسي -3- [4-[[[2-(2-مثيل-h 1-اندول -3-يل)ايثيل]امينو]مثيل]فنيل]-e-2-2بروبان اميد
UA95289C2 (en) Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
IN2015DN00910A (enExample)
UA97243C2 (en) Crystalline anhydrous form of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
CY1117493T1 (el) Αλατα του ν-υδροξυ-3-[4-[[[2-(2-μεθυλ-1η-ινδολ-3-υλ)αιθυλ]αμινο]μεθυλο]φαινυλο]-2ε-2-προπεναμιδιου
DOP2008000069A (es) Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]]fenil]-2e-2-propenamida.
CY1114470T1 (el) Διαδικασια για την παρασκευη ν- υδροξυ-3-ý4-ýýý2-(2-μεθυλο-1η-ινδολ-3- υλ) αιθυλο ¨αμινο¨ μεθυλο ¨φαινυλο¨-2ε-2- προπεναμιδιου και τα υλικα εναρξης αυτων